Bohnemeier H, Pinto Y M, Horkay F, Tóth M, Juhász-Nagy A, Orzechowski H D, Paul M
Department of Cardiovascular Surgery, Semmelweis Medical School, Budapest, Hungary.
J Cardiovasc Pharmacol. 1998;31 Suppl 1:S52-4. doi: 10.1097/00005344-199800001-00017.
Endothelin-converting enzyme-1 (ECE-1) plays a substantial role in activation of the endothelin (ET) system by cleaving the precursor, big ET-1, to the active peptide ET-1. The aim of this study was to investigate whether ECE-1 mRNA expression is modified in human cardiovascular disease. ECE-1 expression was related to echocardiographic data, drug treatment, age, sex, and NYHA heart failure classification. A quantitative PCR assay (qPCR) was established to measure ECE-1 mRNA in these samples. The ECE-1 measurements were normalized over a simultaneously performed GAPDH qPCR. The results indicate a higher ECE-1 expression level in atrial tissue samples of patients who have experienced a myocardial infarction compared with those who did not (ECE-1/GAPDH: 5.81 +/- 0.76 fg/ng; n = 21 vs. 3.20 +/- 0.51 fg/ng; n = 22; p = 0.007). The transverse diameter of the left atrium over 37 mm was associated with a lower ECE-1 expression (ECE-1/GAPDH: 3.11 +/- 0.69 fg/ng; n = 18 vs. 5.12 +/- 0.65 fg/ng; n = 25; p = 0.044). In assessing the drug treatment, decreased ECE-1 expression could be observed in patients who received a beta-blocker (ECE-1/GAPDH: 3.90 +/- 58 fg/ng; n = 31 vs. 5.81 +/- 0.76 fg/ng; n = 12; p = 0.077). These data suggest an involvement of the ET system is cardiovascular disease that may be clinically important.
内皮素转换酶-1（ECE-1）通过将前体大内皮素-1裂解为活性肽内皮素-1，在内皮素（ET）系统的激活中发挥重要作用。本研究的目的是调查人类心血管疾病中ECE-1 mRNA表达是否发生改变。ECE-1表达与超声心动图数据、药物治疗、年龄、性别及纽约心脏协会（NYHA）心力衰竭分级相关。建立了定量聚合酶链反应检测法（qPCR）来测量这些样本中的ECE-1 mRNA。ECE-1测量值通过同时进行的甘油醛-3-磷酸脱氢酶（GAPDH）qPCR进行标准化。结果表明，与未发生心肌梗死的患者相比，发生过心肌梗死的患者心房组织样本中ECE-1表达水平更高（ECE-1/GAPDH：5.81±0.76 fg/ng；n = 21 对比 3.20±0.51 fg/ng；n = 22；p = 0.007）。左心房横径超过37 mm与较低的ECE-1表达相关（ECE-1/GAPDH：3.11±0.69 fg/ng；n = 18 对比 5.12±0.65 fg/ng；n = 25；p = 0.044）。在评估药物治疗时，接受β受体阻滞剂治疗的患者中可观察到ECE-1表达降低（ECE-1/GAPDH：3.90±58 fg/ng；n = 31 对比 5.81±0.76 fg/ng；n = 12；p = 0.077）。这些数据表明ET系统参与心血管疾病，这可能具有临床重要性。
